Is New Zealand’s Regulation of Nanomedicines Adequate?
This article investigates the adequacy of New Zealand's regulation of medical products produced by nanotechnology and containing nanomaterials. There is concern that the novel and unique properties of some nanoscale chemical substances will bring unforeseen human and environmental health and safety risks. Given the possible market for nanomedicines and their potential risks, it is important to have adequate regulation of nanomedicines in order to prevent adverse public health ramifications. This article argues that nanoparticles, invisible to the human eye, are illuminating and exacerbating, legislative imperfections in the Medicines Act 1981 (NZ). This Act does not include a pre-market approval process for medical devices, nor does it include provisions for combination products. This approach is inconsistent with international norms. The article proposes amendment of the Medicines Act 1981 (NZ) to address these weaknesses and the novel challenges posed by nanomedicines.
Publisher: Thomson Reuters
Rights Statement: Please note that this article is being provided for research purposes and is not to be reproduced in any way. If you refer to the article, please ensure you acknowledge both the publication and the publisher appropriately. The citation for the journal is available in the footline of each page. Should you wish to reproduce this article, either in part of in its entirety, in any medium, please ensure you seek permission from our Permissions Officer. Email: LTA.firstname.lastname@example.org
Keywords: nanomedicine; regulation of nanotechnology; medicines legislation; medical devices; pharmaceuticals; risk
Research Type: Journal Article